Carrasco-Hernandez, LauraGiron-Moreno, Rosa M.Pelaez, AdrianGomez-Bonilla, AinhoaGomez-Crespo, BeatrizDiab-Caceres, LaylaTejedor-Ortiz, Ma TeresaGarcia-Clemente, MartaSolis-Garcia, MartaGonzalez-Torres, LuciaBlanco-Aparicio, MarinaOlveira-Fuster, CasildaGiron-Fernandez, Ma VictoriaZamarron-de-Lucas, EstherPrados-Sanchez, ConchaQuintana-Gallego, Esther2023-05-032023-05-032022-09-01Carrasco Hernández L, Girón Moreno RM, Peláez A, Gómez Bonilla A, Gómez Crespo B, et al. Real Life With Tezacaftor and Ivacaftor in Adult Patients With Cystic Fibrosis: Spanish Multicenter Study. Arch Bronconeumol. 2022 Sep;58(9):672-674. English, Spanish0300-2896http://hdl.handle.net/10668/22018Cystic fibrosis (CF) is an autosomal recessive, multisystem genetic disease that mainly affects the exocrine glands due to the absence or alteration of a protein, called cystic fibrosis transmembrane conductance regulator (CFTR).1,2 Until a decade ago, the only treatments available tried to control or prevent the symptoms that were occurring. However, in recent years a line of treatments that improve the functionality of the altered protein has been developed, called CFTR modulators. Tezacaftor–ivacaftor (TEZ/IVA) is modulator of CFTR, indicated in a combined administration regimen for the treatment of CF patients ≥ 6 years, homozygous or heterozygous for the F508del mutation with residual function mutations.3 This drug has been available in Spain since October 1, 2019.enCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorTezacaftorIvacaftorPharmaceutical PreparationsSpainExocrine GlandsMutationletterMutaciónEspañaEnfermedades genéticas congénitasGlándulas exocrinasFibrosis Quística10.1016/j.arbres.2022.06.0031579-2129862844000014